Sangamo Therapeutics Inc (NASDAQ:SGMO) – Research analysts at Wedbush lowered their FY2018 earnings per share estimates for shares of Sangamo Therapeutics in a research report issued to clients and investors on Monday, November 19th. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings per share of ($0.67) for the year, down from their prior estimate of ($0.58). Wedbush has a “Hold” rating and a $11.00 price objective on the stock. Wedbush also issued estimates for Sangamo Therapeutics’ Q4 2018 earnings at ($0.15) EPS, Q1 2019 earnings at ($0.10) EPS, Q2 2019 earnings at ($0.12) EPS, Q3 2019 earnings at ($0.13) EPS, Q4 2019 earnings at ($0.15) EPS, FY2019 earnings at ($0.49) EPS, FY2020 earnings at ($1.32) EPS, FY2021 earnings at ($1.62) EPS and FY2022 earnings at ($1.64) EPS.
A number of other equities research analysts also recently commented on SGMO. BidaskClub raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine downgraded Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 6th. Finally, Guggenheim started coverage on Sangamo Therapeutics in a research report on Tuesday, October 9th. They issued a “buy” rating and a $18.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $19.71.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. The business had revenue of $23.56 million during the quarter, compared to the consensus estimate of $26.96 million. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The business’s revenue for the quarter was up 99.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.15) earnings per share.
Hedge funds have recently bought and sold shares of the business. United Services Automobile Association grew its position in Sangamo Therapeutics by 9.2% during the second quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock valued at $818,000 after acquiring an additional 4,860 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Sangamo Therapeutics by 42.2% during the second quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after purchasing an additional 234,346 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Sangamo Therapeutics by 14.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock worth $8,032,000 after purchasing an additional 71,134 shares in the last quarter. Platinum Investment Management Ltd. acquired a new position in shares of Sangamo Therapeutics during the second quarter worth about $751,000. Finally, Bain Capital Public Equity Management LLC acquired a new position in shares of Sangamo Therapeutics during the second quarter worth about $2,002,000. 65.90% of the stock is owned by hedge funds and other institutional investors.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the business’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $14.66, for a total transaction of $73,300.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $179,585. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director H Stewart Parker purchased 2,000 shares of the stock in a transaction on Friday, September 7th. The shares were purchased at an average cost of $13.52 per share, with a total value of $27,040.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 30,000 shares of company stock valued at $405,400. 1.20% of the stock is owned by company insiders.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Featured Article: How does inflation affect different investments?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.